Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal CancerMarketBeat · 22 hr ago
Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC WainwrightDefense World · 6 days ago
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 CatalystsDefense World · Oct 18, 2026
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 CatalystsMarketBeat · Oct 16, 2026
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual ConferenceGlobeNewsWire · Oct 14, 2026
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerGlobeNewsWire · Sep 22, 2026Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.22 | -$0.23 | Miss |
| Apr 1, 2026 | -$0.28 | -$0.07 | Beat |
| Mar 23, 2026 | -$0.19 | -$0.11 | Beat |
| Aug 12, 2025 | -$0.32 | -$0.23 | Beat |
| Mar 24, 2025 | -$0.33 | -$0.29 | Beat |
| Jul 25, 2024 | -$0.41 | -$0.31 | Beat |